ストックスクリーナーアプリを入手
1.15
8.49%
0.09
プレマーケット:
1.17
0.02
+1.74%
前日終値:
$1.06
開ける：
$1.12
24時間の取引高:
2.86M
Relative Volume:
2.34
時価総額：
$80.94M
収益：
-
当期純損益:
$-37.34M
株価収益率:
-0.8456
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
+23.86%
1か月 パフォーマンス:
+29.50%
6か月 パフォーマンス:
+3.60%
1年 パフォーマンス:
+118.42%
1日の値動き範囲:
$1.10
$1.18
1週間の範囲:
$0.95
$1.18
52週間の値動き範囲:
$0.4986
$1.72
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
SLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.15 | 80.94M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
SELLAS Life Sciences amends executive severance agreements - MSN
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - Defense World
SELLAS Life Sciences Group Inc (NASDAQ: SLS): Blank Check On Growth? - Stocks Register
SELLAS Life Sciences Group Approves Amendments to Change in Control Severance Agreements - Defense World
SELLAS Life Sciences amends executive severance agreements By Investing.com - Investing.com Nigeria
SELLAS Life Sciences Amends Severance for Key Executives - TipRanks
Analyze SELLAS Life Sciences Group Inc (NASDAQ: SLS) Before Investing. - Stocks Register
Geode Capital Management LLC Has $757,000 Position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS advances cancer drug trials, eyes key 2025 milestones - Investing.com
SELLAS Announces Key Business Objectives for 2025 - GlobeNewswire
SELLAS Life Sciences' Cancer Drug Shows 3x Better Survival Rate in Advanced Leukemia Study - StockTitan
State Street Corp Increases Stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - GlobeNewswire
SELLAS Life Sciences Announces 2025 Corporate Strategy Call with CEO and Cancer Expert - StockTitan
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December - MarketBeat
62,785 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by XTX Topco Ltd - Defense World
United Rentals (URI-N) QuotePress Release - The Globe and Mail
SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia - Marketscreener.com
SELLAS Life Sciences Advances Phase 3 AML Trial - TipRanks
SELLAS triggers interim analysis in AML trial - Investing.com
SELLAS triggers interim analysis in AML trial By Investing.com - Investing.com Canada
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - GlobeNewswire
SELLAS Life Sciences Hits Major Milestone in Phase 3 AML Cancer Treatment Trial - StockTitan
SELLAS reports promising AML drug trial results By Investing.com - Investing.com Canada
SELLAS reports promising AML drug trial results - Investing.com India
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML - The Manila Times
SELLAS Announces Positive Overall Survival and Overall - GlobeNewswire
SELLAS' SLS009 Triples Survival Time in Phase 2 AML Trial, Shows Breakthrough Response Rates - StockTitan
Anson Funds Management LP Purchases Shares of 793,835 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - MarketBeat
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers - Yahoo Finance
SELLAS Announces Positive Data from Preclinical Studies - GlobeNewswire
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor - The Bakersfield Californian
SELLAS Life Sciences' SLS009 Shows 67% Efficacy in ASXL1-Mutated Cancer Study | SLS Stock News - StockTitan
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely - Simply Wall St
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate - Yahoo Finance
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
SELLAS Reports 31% Response Rate in AML Trial, Narrows Q3 Loss to $7.1M | SLS Stock News - StockTitan
Highbridge Capital Management's Strategic Acquisition of SELLAS Life Sciences Shares - GuruFocus.com
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewswire
Northrop Grumman Corp (NOC-N) QuotePress Release - The Globe and Mail
SELLAS' Cancer Drug Shows 50% Response Rate in Leukemia Trial, Doubles Survival Time | SLS Stock News - StockTitan
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest - MarketBeat
Galinpepimut-S Gets Rare Pediatric Disease Designation for AML - Hematology Advisor
FDA grants rare pediatric disease designation to SELLAS cancer drug By Investing.com - Investing.com Australia
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S - The Bakersfield Californian
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - StockTitan
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Trading Day Triumph: SELLAS Life Sciences Group Inc (SLS) Ends at 1.19, a -2.46 Surge/Plunge - The Dwinnex
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):